skip to content
Primary navigation


Drug - Vuity™ (pilocarpine 1.25% ophthalmic solution) [Abbvie Inc.]

April 2022

Therapeutic area - Ophthalmics Agents

Initial approval criteria

  • Patient has a diagnosis of presbyopia AND
  • Patient is 40 to 55 years of age AND
  • Vuity is prescribed by or in consultation with an optometrist or ophthalmologist AND
  • Patient has a documented contraindication and/or failure of corrective lenses (eyeglasses or contacts) to resolve presbyopia symptoms AND
  • Patient does not have a hypersensitivity to pilocarpine or any other component of the product AND
  • Patient does not have glaucoma or ocular hypertension AND
  • Patient will NOT receive concomitant treatment with any other ophthalmic pilocarpine formulation AND
  • Patient has been counseled to seek immediate medical care if they experience sudden onset of vision loss AND
  • Patient does not have iritis AND
  • For contact wearers, the patient has been advised to remove contact lenses prior to instillation of Vuity drops and to wait 10 minutes after dosing to reinsert contact lenses.
  • Initial approval is for 6 months

Renewal criteria

  • Patient continues to meet the above criteria AND
  • Patient experienced disease response as indicated by improvement in presbyopia AND
  • Patient is free of unacceptable toxicity from the drug (e.g., retinal detachment event, iritis, hypersensitivity to Vuity)
  • Renewal is for 12 months

Quantity limits

  • 1 bottle (2.5 mL) per 25 days


MHCP Provider Resource Center 651-431-2700 or 1-800-366-5411

back to top